File this under “Not a moment too soon.”
After years of back-and-forth deliberations, the U.S. Food and Drug Administration has agreed to review a rare disease drug developed by a small company that planned to shelve further work if the agency did not take this long-sought step.
Specifically, the FDA accepted a new drug application from Stealth BioTherapeutics for a treatment to combat Barth syndrome, which causes an enlarged heart, muscle weakness, and a shortened life expectancy. The agency also announced it would hold an advisory committee meeting to review the application, but no date has been set. However, the FDA did not issue a priority review, which could delay approval.
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.